USA PhRMA’s Anne McDonald Pritchett PhD highlights the remarkable development of cell and gene therapies in recent years and the three ways in which the US healthcare system can better accommodate them: creating manufacturing systems that take treatment timelines into account, a health system that values treatments based on patient outcomes,…
USA In a bid to make tangible progress on the issue of lowering prescription drug pricing before the 2020 presidential election, the Trump administration is planning to import cheaper medicines from Canada and elsewhere. However, as the Eurasia Group’s Aditya Bhattacharji and Sandra Yamin Namoos outline, the proposed plan’s impact on…
USA PwC’s Kelly Barnes examines how the US pharmaceutical sector is having to rethink its relationship with consumers, experimenting with new and innovative pricing models, and adopting a more holistic view of the patients using their medicines. American consumers want more than just lower prices from pharmaceutical companies US Consumers…
USA Eurasia Group’s Aditya Bhattacharji looks at the potentially damaging fallout of the ongoing US-China trade war on the life sciences industry. Biotech [is the] new frontier for US-China tensions The G20 gathering in Osaka at the end of June was, overall, less tense than other multilateral fora over the…
Sweden The American Chamber of Commerce in Sweden promotes trade and investment between the USA and Sweden. Peter Dahlen, AmCham Sweden’s managing director, outlines the significance of Swedish American ties, both macroeconomically and from a healthcare investment standpoint. This is in addition to the success of American companies in the country…
China Dr Shun Luo, chairman, founder and CEO of Thousand Oaks Biopharmaceuticals, shares the company’s vision to deliver more accessible and affordable biologics to patients globally by lowering the cost of goods manufactured (COGM) per gram of recombinant protein; the paradigm-shifting technology and processes Thousand Oaks Biopharmaceuticals is innovating as an…
USA The bestselling drugs of 2018 in the USD 485 billion US pharma market. The list features several major blockbusters benefiting from the delays in biosimilar approval in the US, as well as several small-molecule medications that stand to lose out to generic competition in the coming years. AbbVie’s Humira is…
USA Christopher P. Molineaux of Life Sciences Pennsylvania outlines the Keystone State’s rich lineage of pharmaceutical innovation, how the association is building inter-state and international connections, and why Philadelphia is justified in branding itself as the ‘Cellicon Valley’. We are at the epicentre of cell and gene therapy, what we…
USA Chip Davis of the Association for Accessible Medicines argues that learning from the European biosimilars approval experience could speed up patient access to these complex drugs in the USA. Advancements in biologic research and development have brought forth life-saving treatments for patients with cancer as well as such chronic…
USA US industry veteran Sharon Ayd describes her journey to becoming a pharma company board member, the various hurdles still facing female pharma executives, and the responsibility of women at the top to “pay it back” and help the next generation of female leaders. As I climbed the corporate ladder,…
Canada A new white paper from Fasken law firm asserts that the early filing of patents for innovative products is crucial for companies hoping to succeed in the booming North American cannabis market Canada’s decision to legalise cannabis for recreational use in 2018 is set to spur on the already…
USA Meghann Chilcott offers an introductory look at the potential of customer data platforms (CDPs) to transform the way pharmacy marketers reach out to an increasingly online customer base in the USA. CDPs enable marketers to pool customer information together from various sources for the purpose of creating seamless, data-rich…
See our Cookie Privacy Policy Here